Rheumatic disease and COVID-19: epidemiology and outcomes

Kimme L Hyrich; Pedro M Machado

doi:10.1038/s41584-020-00562-2

Rheumatic disease and COVID-19: epidemiology and outcomes

Nat Rev Rheumatol. 2021 Feb;17(2):71-72. doi: 10.1038/s41584-020-00562-2.

Authors

Kimme L Hyrich¹, Pedro M Machado²

Affiliations

¹ Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. kimme.hyrich@manchester.ac.uk.
² Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.

Abstract

Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have been identified. Whether patients with rheumatic diseases, especially those receiving DMARDs, are at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease remains unclear, although epidemiological studies are providing some insight.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antirheumatic Agents / therapeutic use*
COVID-19 / mortality*
Humans
Rheumatic Diseases / complications*
Rheumatic Diseases / drug therapy

Substances

Antirheumatic Agents